

Vilija Oke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3273811/publications.pdf>

Version: 2024-02-01

12
papers

603
citations

933264

10
h-index

1125617

13
g-index

14
all docs

14
docs citations

14
times ranked

971
citing authors

#	ARTICLE	IF	CITATIONS
1	The immunobiology of Ro52 (TRIM21) in autoimmunity: A critical review. <i>Journal of Autoimmunity</i> , 2012, 39, 77-82.	3.0	142
2	High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2019, 21, 107.	1.6	129
3	TNF- α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000260.	1.1	73
4	High Ro52 Expression in Spontaneous and UV-Induced Cutaneous Inflammation. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2000-2010.	0.3	56
5	IFN- γ 1 with Th17 axis cytokines and IFN- α define different subsets in systemic lupus erythematosus (SLE). <i>Arthritis Research and Therapy</i> , 2017, 19, 139.	1.6	54
6	Interferon (IFN)- γ is a potential mediator in lupus nephritis. <i>Lupus Science and Medicine</i> , 2016, 3, e000170.	1.1	48
7	Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State. <i>Journal of Rheumatology</i> , 2020, 47, 865-875.	1.0	28
8	Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations. <i>ACR Open Rheumatology</i> , 2022, 4, 27-39.	0.9	25
9	Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11327.	1.8	20
10	Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. <i>Arthritis Research and Therapy</i> , 2021, 23, 132.	1.6	12
11	Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1029.	2.2	11
12	Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment. <i>Rheumatology</i> , 2021, 60, 1445-1455.	0.9	4